Outcomes Measurement: Health State Preferences and Economic Evaluation

Assistive Technology

Volumn 8, Issue 2, 1996, Pages 94-102

  Oldridge, Neil B ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Assistive technology; Cost benefit analysis; Cost effectiveness; Health care technology evaluation; Health services research; Health status indicators; Outcomes research; Quality of life

Indexed keywords

COST ACCOUNTING; ECONOMIC AND SOCIAL EFFECTS; EVALUATION; HEALTH CARE; QUALITY CONTROL;

ASSISTIVE TECHNOLOGY; COST-BENEFIT ANALYSIS; HEALTH CARE TECHNOLOGY; HEALTH SERVICES RESEARCH; QUALITY OF LIFE;

MEDICAL PROBLEMS;

DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH STATUS; MEDICAL TECHNOLOGY; OUTCOMES RESEARCH; QUALITY OF LIFE; REVIEW;

COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HEALTH STATUS INDICATORS; HUMANS; LIFE EXPECTANCY; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TECHNOLOGY, HIGH-COST;

EID: 0030474995     PISSN: 10400435     EISSN: 19493614     Source Type: Journal    
DOI: 10.1080/10400435.1996.10132279     Document Type: Article

References (48)

1. Bennett, K., & Torrance, G. (1996). Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (pp. 253-265). Philadelphia: Lippincott-Raven
2. Canadian Coordinating Office for Health Technology Assessment. (1994). Guidelines for the economic evaluation of pharmaceuticals: Canada (1st ed.). Ottawa: CCHOTA. Commonwealth of Australia. (1993). Background document on the use of economic evaluation as a basis for the inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme. Canberra: Australian Government Publishing Service
3. Detsky, A., & Naglie, I. (1990). A clinician’s guide to cost-effectiveness analysis. Annals of Internal Medicine, 113, 147-154
4. Doubilet, P., Weinstein, M., & McNeil, B. (1986). Use and misuse of the term “cost-effective” in medicine. New England Journal of Medicine, 314, 253-256
5. Drummond, M., Stoddart, G., Labelle, R., & Cushman, R. (1987). Health economics: An introduction for clinicians. Annals of Internal Medicine, 107, 88-92
6. Drummond, M., Stoddart, G., & Torrance, G. (1988). Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press
7. Drummond, M. F., Torrance, G. W., & Mason, J. (1993). Cost- effectiveness league tables; More harm than good? Social Science in Medicine, 37, 33-40
8. Eddy, D., & Billings, J. (1988). The quality of medical evidence: Implications for quality of care. Health Affairs, Spring, 1932
9. Eisenberg, J. (1989). Clinical economics: A guide to the economic analysis of clinical practice. Journal of the American Medical Association, 262, 2879-2886
10. Ellwood, P. (1988). Shattuck lecture-Outcomes management. New England Journal of Medicine, 318, 1549-1556
11. Epstein, A. (1995). Evaluating the cost-effectiveness of pharmacologic therapy: Where we’ve been and where we’re going. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 70(Suppl. 4), S1-S5
12. Feeny, D., Furlong, W., Boyle, M., & Torrance, G. (1995). Multi-attribute health status classification systems. Health Utility Index. PharmacoEconomics, 7, 490-502
13. Feeny, D., Furlong, W., & Torrance, G. (1996). Health Utilities Index. In B. Spilker (Ed.), Quality of life and pharmacoe- conomics in clinical trials (pp. 239-252). Philadelphia: Lip- pincott-Raven
14. Freund, D., & Dittus, R. (1992). Principles of pharmacoecon- omic analysis of drug therapy. PharmacoEconomics, 1, 2032
15. Ganiats, T., & Schneiderman, L. (1988). Principles of cost-effectiveness research. Journal of Family Practice, 27, 77-84
16. Goldman, L., Gordon, D., Rifkind, B., Hulley, S., Detsky, A., Goodman, D., Kinosian, B., & Weinstein, M. (1992). Cost and health implications of cholesterol lowering. Circulation, 85, 1960-1968
17. Goldman, L., Garber, A., Grover, S., & Hlatky, M. (1996). Cost effectiveness of assessment and management of risk factors. Journal of the American Colie. of Cardiology, 27, 1020-1030
18. Guyatt, G., Feeny, D., & Patrick, D. (1993). Measuring health- related quality of life. Annals of Internal Medicine, 118, 622-629
19. Jonsson, B. (1995). Cost-effectiveness: A new criterion for selecting therapy [Editorial]. Journal of Internal Medicine, 237, 1-3
20. Kalish, S., Gurwitz, J., Krumholz, H., & Avom, J. (1995). A cost-effectiveness model for thrombolytic therapy for acute myocardial infarction. Journal of General Internal Medicine, 10, 321-330
21. Laupacis, A., Feeny, D., Detsky, A., & Tugwell, P. (1992). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadia Medical Associate Journal, 146, 473-481
22. Mater, A., Larson, E., Urban, N., & Deyo, R. (1996). Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. Spine, 21, 1048-1055
23. McMaster University Department of Clinical Epidemiology and Biostatistics (1984a). How to read clinical journals: VII. To understand an economic evaluation [Part A]. Canadian Medical Association Journal, 130, 1428-1434
24. McMaster University Department of Clinical Epidemiology and Biostatistics (1984b). How to read clinical journals: VII. To understand an economic evaluation [Part B], Canadian Medical Association Journal, 130, 1542-1549
25. Nord, E. (1992). Methods for quality adjustment of life years. Social Science and Medicine, 34, 559-569
26. O’Connor, G., Buring, J., Yusuf, S., Goldhaber, S., Olmstead, E., Paffenbarger, R., & Hennekens, C. (1989). An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation, 80, 234-244
27. Office of Technology Assessment. (1992). Evaluation of the Oregon Medicaid proposal. OTA-H-531. Washington, DC: U.S. Government Printing Office
28. Oldridge, N. (1995). Universal access and insurance coverage: Missing pieces. Journal of Cardiopulmonary Rehabilitation, 15, 9-13
29. Oldridge, N., Nagle, F., Balke, B., Corliss, R., & Kahn, D. (1978). Aortocoronary bypass surgery. Effects of surgeiy and 12 months of physical conditioning on treadmill performance. Archives of Physical Medicine and Rehabilitation, 59, 268-275
30. Oldridge, N., Guyatt, G., Fischer, M., & Rimm, A. (1988). Cardiac rehabilitation after myocardial infarction: Combining data from randomized clinical trials. Journal of the American Medical Association, 260, 945-980
31. Oldridge, N., Guyatt, G., Jones, N., Crowe, J., Singer, J., Feeny, D., McKelvie, R., Runions, J., Streiner, D., & Torrance, G. (1991). Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. American Journal of Cardiology, 67, 1084-1089
32. Oldridge, N., Furlong, W., Feeny, D., Torrance, G., Guyatt, G., Crowe, J., & Jones, N. (1993). Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. American Journal of Cardiology, 72, 154-161
33. Oldridge, N., Zhong, Y., Stoll, J., & Rimm, A. (1994). Lumbar spine surgery and mortality among Medicare beneficiaries, 1986. American Journal of Public Health, 84, 1292-1298
34. Oregon Health Services Commission. (1991). Prioritization of health services: A report to the Governor and Legislature. Salem: Oregon Health Services Commission
35. Patrick, D., & Erickson, P. (1993). Health status and health policy. Quality of life in health care evaluation and resource allocation. New York: Oxford University Press
36. Rechnitzer, P., Cunningham, D., Andrew, G., Buck, C., Jones, N., Kavanagh, T., Oldridge, N., Parker, J., Shephard, R., & Sutton, J. (1983). The relation of exercise to the recurrence rate of myocardial infarction in men. Ontario Exercise-Heart Collaborative Study. American Journal of Cardiology, 51, 65-69
37. Reiman, A. (1988). Assessment and accountability. The third revolution in medical care. New England Journal of Medicine, 319, 1220-1222
38. Robinson, R. (1993). Economic evaluation and health care: What does it mean? Br Med J, 307, 670-673
39. Spilker, B. (Ed.). (1996). Quality of life and pharmacoecon- omics in clinical trials. Philadelphia: Lippincott-Raven
40. Testa, M., & Simonson, D. (1996). Assessment of quality of life outcomes. New England Journal Medicine, 334, 835-840
41. Torrance, G. (1986). Measurement of health state utilities for economic appraisal. A review. Journal of Health Economics, 5, 1-30
42. Torrance, G. (1987). Utility approach to measuring health-related quality of life. J Chron Dis, 40, 593-600
43. Torrance, G., & Feeny, D. (1989). Utilities and quality-adjusted life years. Int J Technol Assess Health Care, 5, 559-575
44. Torrance, G., Furlong, W., Feeny, D., & Boyle, M. (1995). Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics, 7, 503-520
45. U.S. Department of Health and Human Services. (1993). Research plan for the National Center for Medical Rehabilitation Research. Rockville, MD: U.S. Department of Health and Human Services, National Institutes of Health
46. Ware, J., Jr. (1996). The SF-36 health survey. In B. Spilker (Eds.), Quality of life and pharmacoeconomics in clinical trials (pp. 337-345). Philadelphia: Lippincott-Raven
47. Ware, J., Jr., & Sherbourne, C. (1992). The MOS 36-item short- form health survey (SF-36). I. Conceptual framework and item selection. Medica Care, 30, 473-483
48. Weinstein, M., & Stason, W. (1977). Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine, 296, 716-721